Consequently, we analyzed the effects of combinations of AZ1 with venetoclax or ibrutinib on CLL patient cells with NOTCH1 mutations or activated NOTCH1 signaling defined by high NICD protein expression and compared them to the effects on CLL cells without NOTCH1 mutations and low NICD levels. Here, NOTCH1 is linked to B-cell chronic lymphocytic leukemia.